GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Locust Walk Acquisition Corp (NAS:LWACW) » Definitions » Inventories, Raw Materials & Components

LWACW (Locust Walk Acquisition) Inventories, Raw Materials & Components : $0.00 Mil (As of Oct. 2020)


View and export this data going back to 2021. Start your Free Trial

What is Locust Walk Acquisition Inventories, Raw Materials & Components?

Locust Walk Acquisition's inventories, raw materials & components for the quarter that ended in Oct. 2020 was $0.00 Mil.

Locust Walk Acquisition Inventories, Raw Materials & Components Historical Data

The historical data trend for Locust Walk Acquisition's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Locust Walk Acquisition Inventories, Raw Materials & Components Chart

Locust Walk Acquisition Annual Data
Trend
Inventories, Raw Materials & Components

Locust Walk Acquisition Semi-Annual Data
Oct20
Inventories, Raw Materials & Components -

Locust Walk Acquisition Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

Locust Walk Acquisition Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Locust Walk Acquisition Corp (NAS:LWACW) » Definitions » Inventories, Raw Materials & Components
Comparable Companies
Traded in Other Exchanges
N/A
Address
200 Clarendon Street, 51st Floor, Boston, MA, USA, 02116
Website
https://www.locustwalkacquisitioncorp.com
Locust Walk Acquisition Corp is a blank check company.

Locust Walk Acquisition Headlines

From GuruFocus

Locust Walk Acquisition Corp. Class A Common Shares and Warrants to Commence Trading Separately on March 1, 2021

By PRNewswire PRNewswire • 02-23-2021

eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies

By Marketwired Marketwired • 05-27-2021

Locust Walk Acquisition Corp.'s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies

By Marketwired Marketwired • 08-24-2021

eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

By Marketwired Marketwired • 07-22-2021

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies

By Marketwired Marketwired • 08-26-2021

Locust Walk Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q Stemming from SEC Guidance Concerning Balance Sheet Treatment of Warrants

By Marketwired Marketwired • 06-03-2021

eFFECTOR Therapeutics Announces Publication of Tomivosertib Preclinical Data in Cell Reports

By Marketwired Marketwired • 07-16-2021

Locust Walk Acquisition Corp. Announces Completion of $175,000,000 Initial Public Offering, Including Exercise of Over-Allotment Option

By PRNewswire PRNewswire • 01-13-2021